Articles tagged with Cancer Medication
A UC Davis study found a critical agent keeping KSHV dormant and undetected by the immune system. The virus is linked to various cancers and AIDS-related diseases. The researchers identified CHD4 as a key regulator of the latency-lytic switch, allowing the virus to stay silent.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
Researchers identified a relationship between genetic mutations that promote cancer growth and those that help cells evade the immune system. This finding has implications for developing more effective immunotherapies by understanding how cancer cells balance growth and invisibility.
Researchers at Weill Cornell Medicine found that tumors recruit nearby cells called fibroblasts to work as their enablers by releasing lactate. This finding suggests that future drug treatments could target this defense mechanism to help cancer patients.
Researchers found phosphatidylinositol bisphosphate (PIP2) essential for epithelial cell-cell adhesion and maintaining cellular identity. PIP2 regulates epithelial properties by recruiting Par3 to the plasma membrane, facilitating the formation of adherens junctions and preventing epithelial-mesenchymal transformation.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Cancer incidence is projected to double in SSA by 2040, with 1.4 million cases per year expected without rapid interventions. Women are more affected by cancer than men in the region, with breast and cervical cancers among the most common types.
Researchers developed a droplet-based microfluidic technology to produce micro-organospheres from cancer patient biopsies within an hour. These miniature tumors retain the original microenvironment and can be used for testing many drug conditions, showing almost perfect correlation with actual clinical treatment outcomes.
A recent study by Weill Cornell Medicine and Dana Farber Cancer Institute reveals that CDC7 is replaceable by CDK1 in cell division, opening up new avenues for cancer therapies. The finding highlights the complex molecular orchestration of the cell cycle and suggests a powerful new strategy against cancer.
The S1216 study showed an unprecedented median OS of 70 months in the control arm, outperforming previous results by 24 months. This extended survival was attributed to additional life-prolonging treatments patients received after completing the trial therapy.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
A new study from Montefiore Einstein Cancer Center found that CAR-T therapy was effective in Black and Hispanic patients, with outcomes comparable to those of white and Asian patients. The study showed no statistical differences in clinical outcomes or side effects among racial and ethnic backgrounds.
The composition of microorganisms living in the gut influences response to conventional cancer treatments and novel immunotherapies. Recent studies suggest that targeting the gut microbiome could diminish side effects of chemotherapy, while diet, probiotics, and antibiotic medications may also impact clinical responses.
Cancer cells employ a unique defense mechanism to evade the effects of radiation treatment by exploiting an enzyme called Caspase-activated DNase (CAD). Removing CAD from cancer cells increases the effectiveness of radiotherapy. Researchers hope their discovery can lead to the development of targeted drugs to enhance cancer treatment.
Researchers from Columbia University have developed a plug-and-play multi-organ chip, customized to the patient, consisting of engineered human heart, bone, liver, and skin linked by vascular flow. The model allows for long-term studies and can be optimized for personalized therapy optimization in cancer and systemic diseases.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Texas A&M University developed a low-cost, minimally invasive wireless device that uses photodynamic therapy to kill cancer cells. The device enables precise and safe treatment options during surgery, potentially reducing the need for additional treatments like chemotherapy.
Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.
Deleting or inhibiting a protein called lysine-specific demethylase 1 (LSD1) may curb the growth of oral squamous cell carcinoma tumors. The study found that disrupting LSD1 promotes anti-tumor immunity, which can help fight cancer. The discovery could lead to new and potentially more effective therapies for oral cancer patients.
A study by Brigham and Women's Hospital found that more than half of cancer centers do not publicly disclose payer-specific prices for patients with private health insurance. The study also revealed significant markups in drug prices, ranging from 120% to 630% above the hospital cost.
Research from Weill Cornell Medicine found that less prostate cancer screening has reduced overdiagnosis, but increased incidence of high-grade and metastatic disease. The study analyzed over 438,000 men with newly diagnosed prostate cancer between 2010 and 2018.
A study published in Cancer Medicine suggests that exosomes produced by adipose-derived mesenchymal stem cells can effectively deliver RNA-based anti-cancer treatments to bladder cancer tumors. This novel approach shows promise as a potential therapeutic agent for bladder cancer treatment, offering new hope for patients.
The ESMO Breast Cancer Congress 2022 event will present more than 200 studies on various aspects of breast cancer, including new treatments and innovative clinical practices. The congress will be held onsite in Berlin, Germany, and online, offering a platform for breast cancer specialists to share knowledge and improve patient outcomes.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
Researchers at Aarhus University have developed improved DNA nanostructures that can assemble biomolecules with multiple functions, increasing the effectiveness of cancer treatment. The new structures are more stable, non-toxic, and immune system-friendly than previous versions.
Researchers are developing radioconjugate drugs that combine radiation with a tumor-targeting agent to selectively kill cancer cells. Two approved drugs, Lutathera and Pluvicto, demonstrate the potential of this therapy, which could change the future of cancer treatment.
A new study reveals a gene called KLF4 that normally suppresses tumor formation but is reprogrammed in acute promyelocytic leukemia, an aggressive type of blood cancer. Overexpressing KLF4 can suppress the growth of cancerous cells and reverse the effects of the disease.
Researchers at Charité - Universitätsmedizin Berlin have discovered a novel mechanism that restricts cell division in healthy stomach tissue, protecting against cancerous changes. However, Helicobacter pylori infection deactivates this mechanism, enabling cells to grow uncontrollably and increasing the risk of stomach cancer.
Researchers at the Lewis Katz School of Medicine defined 11 subsets of cells found in esophageal tissue using single cell gene-expression profiling. This study could help clinicians diagnose or treat certain types of cancer by identifying functional cell types contributing to cancer progression.
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
The TTUHSC's C. Patrick Reynolds has received a $1.34 million CPRIT grant to investigate updating the clinical risk stratification scale for neuroblastoma and rhabdomyosarcoma, two childhood cancers in need of improved therapies.
A phase two randomised placebo controlled trial showed giving patients nintedanib, as well as chemotherapy before surgery or radiotherapy, significantly increased overall survival rates at one, two and five years. Nintedanib blocks different proteins from sending signals to cancer cells to grow, causing the cancer cells to die.
Researchers identified clofarabine as a promising compound with inhibitory effects on bladder cancer cells, including urothelial carcinoma and sarcomatoid carcinoma. The study suggests potential for clinical trials to treat metastatic bladder cancer patients who cannot receive traditional cisplatin-based therapy.
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
The RACE Act has led to an increase in required studies for cancer drugs targeting molecular targets relevant to pediatric cancer. Since its implementation, 42.9% of approved drugs have been required to conduct pediatric studies, up from 8.3% before the act.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
Researchers developed an AI model to predict side effects from new combination therapies by analyzing over 15 million records of adverse events. The model can recognize patterns between drugs and their side effects, enabling the prediction of adverse events for individual therapy profiles.
Researchers at CU Cancer Center have developed a lead drug that inhibits the oncogene CHD1L, a chromatin remodeling enzyme that aids tumor progression and metastasis in many cancer types. The drug, called 6.11, has shown promising biological activity against CHD1L.
Recent studies published in the Journal of Pharmaceutical Analysis have found applications of nanotechnology in medicine, drug research, and environmental protection. Researchers developed nanodots made of carbon using natural polysaccharides from mushrooms to detect chromium, and created nanozymes that could be used to detect drug con...
Scientists at the University of Bath have developed a new technique called Transcription Block Survival (TBS) to accelerate the discovery of cancer-fighting drugs. TBS identifies molecules that can shut down dangerous proteins before they wreak havoc, by blocking their interaction with cell DNA.
Researchers at MUSC have developed a device to remove toxic chemotherapy drugs, such as doxorubicin, from the blood after cancer treatment. The device uses heat and an activated carbon filter to effectively remove the drug, potentially reducing harmful side effects.
A new biodegradable gel has been developed to improve the immune system's ability to combat cancer. The gel releases drugs and special antibodies that target tumor cells, slowing their growth and increasing the lifespan of mice. This breakthrough could lead to new clinical trials for human patients in the coming years.
Researchers have identified a process to study circulating tumor cells responsible for cancer recurrence in patients with non-small cell lung cancer. The study models showed that these cells correlated with cancer recurrence, and blocking a protein called MYC made the tumor cells more vulnerable to chemotherapy.
Researchers have developed a method to chart the first-ever map of allosteric sites in two common human proteins, revealing they are abundant and identifiable. This could lead to safer, smarter, and more effective medicines by targeting these 'secret doors'.
A study found that childhood cancer survivors who received combined chemotherapy and radiotherapy have a higher risk of dental developmental anomalies. The first signs of dental disturbances can appear within one or two years after treatment. Researchers identified specific treatments and age factors associated with increased DDA risk.
Medicare beneficiaries without low-income subsidies were nearly twice as likely to not fill prescriptions for serious health conditions like cancer or hepatitis C treatment, according to a new study from Vanderbilt University Medical Center researchers. The study found that 30% of patients without subsidies did not fill their prescribe...
A study in rats suggests that vitamin C supplementation can help preserve skeletal muscle after doxorubicin therapy, reducing oxidative stress and inflammation. The findings suggest vitamin C may represent a promising opportunity to reduce some of the drug's most debilitating side effects.
A recent study found that cancer treatment side effects significantly affect patients' and caregivers' eating habits, food preferences, and overall well-being. The research team identified six themes, including managing symptoms, losing taste, and caregiver burden.
A new study suggests that cardamonin, a compound from the cardamom spice, can kill triple-negative breast cancer cells and reduce PD-L1 expression. The findings hold promise for improving cancer therapy without severe side effects.
Hokkaido University scientists have identified CDK6 as a promising target for treating adult T-cell leukemia/lymphoma (ATLL) with the drug palbociclib. The combination of palbociclib with everolimus also showed significant tumor growth reduction and minimal side effects in mice models.
Researchers at CU Anschutz Medical Campus discovered a reactivated protein, Hand2, in certain cases of mesothelioma, which may lead to new treatments. The study aims to investigate the cause and effect of this reactivation.
A study led by UCL researchers found significant disparities in opioid painkiller access between countries, with some regions reporting rates as low as 0.01 MME per 1,000/day, while others have surpassed the US in opioid sales. The findings highlight the need for global policies to improve palliative care and pain relief provision.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Researchers at Insilico Medicine have used AI to identify potential targets that are implicated in multiple age-related diseases and also play a role in the basic biology of aging. The study resulted in the identification of 69 high-confidence targets with potential high druggability.
Dr. Elaine S. Jaffe is being recognized for her pioneering work in hematopathology, including the discovery of novel pathological entities and her development of standardized diagnostic criteria for lymphoma and leukemia. She has also made significant contributions to advancing cancer research, diagnosis, treatment, and prevention.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Dr. Tony Hunter's groundbreaking work on protein tyrosine phosphorylation has led to the development of targeted cancer therapies and a deeper understanding of cancer biology. His discovery has been recognized with numerous awards, solidifying his legacy in cancer research.
Researchers developed a method to identify aggressive early-stage lung cancers and target drugs to tumors likely to respond. They used genomics network models and identified signature genes associated with tumor invasiveness.